Firms To Watch: Life sciences

Headed by Jeffrey Fessler and Scott Liebman in New York, and Allison Fulton in Washington DC, Sheppard, Mullin, Richter & Hampton LLP handles pre-market regulatory issues, compliance programs, and clinical trial agreements for pharmaceutical companies and investment companies.

Life sciences in United States

Arnold & Porter

The large team at Arnold & Porter assists a diverse client base consisting of medical device and diagnostic product manufacturers, biologics companies, and vaccine developers. The team assists clients with a variety of mandates, including clinical trials, transactional diligence, and exclusivity matters. Daniel Kracov and Allison Shuren co-head the team; Kracov, in particular, has considerable experience handling congressional investigations concerning biomedical product policies. Jeffrey Handwerker often assists pharmaceutical companies with the implementation of healthcare reforms; Mahnu Davar handles federal enforcement actions, including the misuse of clinical research and foreign kickbacks; and Ariane Horn has ample experience in advising biotechnology companies on FDA regulation, particularly in relation to biological products and pharmaceuticals. Kristin Hicks maintains her focus on price reporting, and routinely advises clients on issues arising under the Medicaid Rebate Act, in addition to PBM and GPO arrangements. Working out of the New York practice, Daniel DiNapoli‘s area of expertise is patent litigation, often representing biotech companies in contentious matters concerning anti-TNF antibody products, transgenic mice, and mainstream drugs. Deborah Fishman supports the team from Silicon Valley with her vast contentious expertise, routinely assisting biopharmaceutical companies with the enforcement of IP rights. All named practitioners are based in Washington DC unless specified otherwise.

Practice head(s):

Dan Kracov; Allison Shuren

Other key lawyers:

Jeffrey Handwerker; Mahnu Davar; Ariane Horn. Kristin Hicks; Murad Hussain; Anand Agneshwar; Daniel DiNapoli; Deborah Fishman

Key clients

Pharmaceutical Research and Manufacturers of America (PhRMA)


Thermo Fisher






Eisai, Inc.

Novo Nordisk

Vertex Pharmaceuticals



Rewrite Therapeutics

Alcon Laboratories, Inc.


Sanofi and Regeneron


Sandoz Inc. and Fougera Pharmaceuticals Inc.

Work highlights

  • Advised Enzyvant on the manufacturing, supply, procurement, and launch activities for RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time regenerative tissuebased therapy for immune reconstitution in pediatric patients with congenital athymia.
  • Represented Novartis in an option, collaboration and license agreement with BeiGene Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology.

Cooley LLP

Cooley LLP's team, known for its ‘reliable bench strength‘ and ‘deep level of commercial and industry expertise', routinely dispenses advice on venture capital financing and company formation. Kay Chandler and Christian Plaza co-head the practice from San Diego and Washington DC, respectively. Chandler often advises both public and private life sciences entities - including pharmaceutical and biotherapeutics companies - while Plaza focuses on transactional work, including public and private offerings, healthcare M&A, and strategic partnerships. Also based in DC, Ken Krisko maintains a transactions-focused practice, as well as advising on licensing agreements and strategic alliances. Ivor Elrifi, who works out of the New York practice, focuses on patent prosecution matters. Key names to note in Palo Alto include Marya Postner, whose expertise includes advising on strategic collaborations concerning research and marketing between biotech and pharmaceutical companies; Kate Hillier, who has vast experience in advising on the development and marketing of medical devices, vaccines, and digital health products; and Laura Berezin, who assists life sciences companies and investment banks - both domestic and overseas - with series financings and securities.

Practice head(s):

Kay Chandler; Christian Plaza

Other key lawyers:

Ivor Elrifi; Kate Hillier; Laura Berezin; Ken Krisko; Marya Postner


‘Cooley has been a loyal and dependable partner over many years advising our company on a broad range of complex matters.’

‘They are highly responsive and have a deep level of commercial and industry expertise. They are flexible and dependable.’

‘Cooley has exceptional leaders and reliable bench strength. I am always impressed by their sophistication, deep knowledge of the industry and passionate representation of and commitment to our company’s interests.’

Key clients

Turning Point Therapeutics

Poseida Therapeutics, Inc.

Jazz Pharmaceuticals


PhaseBio Therapeutics

Artiva Biotherapeutics


Myovant Sciences

CinCor Pharma


Horizon Therapeutics

Neurocrine Biosciences

Arvinas, Inc.

OKYO Pharma, Inc.

Nykode Therapeutics

Autolus Therapeutics

Work highlights

  • Advised Turning Point Therapeutics, a precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb, valued up to $4.1 billion.
  • Advised Poseida Therapeutics on its strategic collaboration and licensing agreement with Roche, valued up to $6 billion.
  • Advised Jazz Pharmaceuticals on two licensing matters: i) an exclusive global licensing agreement with Werewolf Therapeutics, Inc., under which Jazz has acquired exclusive global development and commercialization rights to werewolf’s investigational WTX-613, a differentiated, conditionally activated interferon alpha (IFNα) INDUKINE™ molecule. ii) the exclusive licensing agreement with Sumitomo Pharma Co. Ltd, under which Jazz acquired development and commercialization rights in certain jurisdictions for Sumitomo Pharma’s highly selective oral orexin-2 receptor agonist DSP-0187, which has potential application for the treatment of narcolepsy and other sleep disorders. Overall potential aggregate deal value is approximately $1.09 billion.

Latham & Watkins LLP

Latham & Watkins LLP provides a diverse offering to a number of clients, including biopharmaceutical and biotech start-up companies, and medical device manufacturers. The team advises on a wide range of matters, including white collar investigations, IP disputes, and corporate transactions. Based in California, Shayne Kennedy is particularly adept at advising on public and private securities offerings, and life sciences M&A, while Judith Hasko has a great deal of experience in the execution of strategic licensing alliances, often assisting life sciences companies with securing funding. Arlene Lee Chow works out of the New York office, and routinely acts for biotech and pharmaceutical companies in IP and patent cases. Chicago-based Terra Reynolds is noted for her expertise in government and internal investigations, while the Boston-based Julie Scallen focuses on joint ventures and venture capital transactions within the life sciences and med-tech industries. In Washington DC, John Manthei maintains an FDA regulatory practice with a distinct emphasis on the medical device and biotech industries; Ben Haas has extensive experience in assisting clients with FDA submissions and pre-clinical testing, and Elizabeth Richards often negotiates contracts with clinical trial sites.

Practice head(s):

Robbie McLaren; Arlene Chow; Terra Reynolds; Shayne Kennedy; Eveline Van Keymeulen; John Manthei; Judith Hasko; Ben Haas; Jason Caron

Other key lawyers:

Julie Scallen; Elizabeth Richards; Adam Perlman; Ernest Yakob; Tom Malone


‘Latham’s Medicaid and Medicare government pricing team is the best in the industry. They have an exceptional grasp of complex laws and an unmatched ability to help clients understand and operationalize those laws.’

Key clients

4D Molecular Therapeutics

Abbott Laboratories

ALASTIN Skincare

Altaris Capital Partners

ArchiMed Group

Arcutis Biotherapeutics

Astellas Pharma

Bionomics Limited



Crinetics Pharmaceuticals


Halozyme Therapeutics


Khosla Ventures Acquisition Co.

Environmental Impact Acquisition Corp.


Gritstone bio

Homology Medicines

Johnson & Johnson Surgical Vision

Work highlights

McDermott Will & Emery LLP

Douglas Carsten leads McDermott Will & Emery LLP’s life sciences industry group from Orange County. The ‘quality’ team exhibits ‘industry knowledge and innovative thinking‘ as it advises private equity and venture capital firms investing in life sciences on financings and deals, as well as digital health and technology companies seeking assistance regarding FDA and regulatory issues. Pollard primarily dispenses regulatory and corporate advice to medical device and biotech companies on matters concerning clinical research, post-market safety and compliance with FDA regulated products, and manufacturing. The ‘masterful‘ Carsten is a ‘tremendous litigator‘ who acts in lucrative patent and Hatch-Waxman cases. Working out of the Boston office, Sarah Chapin Columbia focuses on IP and patent litigation, while Michael Siekman assists with the development and defense of biotech patent portfolios and acquisitions. William Gaede supports the team from Silicon Valley with his experience in life science technology IP litigations concerning small molecules, proteins, and diagnostics. Counsel Anisa Mohanty, based in Washington DC, has extensive expertise in pre-market FDA strategy and post-market compliance, often advising medical product manufacturers and biotech companies. Vernessa Pollard departed the team to join DLA Piper LLP (US) in February 2024.

Practice head(s):

Douglas Carsten


‘My dealings with Douglas Carsten and his team have been wonderful. The team is fully staffed and always fully prepared. They are also able to handle a full range of IP technologies.’

‘Douglas is a tremendous litigator. He learns everything about the technology and the business associated with the technology. In court, Doug is masterful. Again, his presentation before the court appears to be effortless and is readily appreciated by judges. Best of all, he is a winner.’

‘They are a quality team.’

‘The team has industry knowledge and innovative thinking.’

Key clients

Kent Thiry, former CEO of DaVita

Merck KgaA

Alnylam Pharmaceuticals

Vanda Pharmaceuticals

CRISPR Therapeutics AG

Baxter International Inc.

Bausch Health Companies Inc.

Ampersand Capital Partners

Zura Bio Limited

Merck & Co.

McDermottPlus Health

United Therapeutics Corporation

Work highlights

  • Represented Merck KGaA, Darmstadt, Germany, in its $780 million acquisition of Exelead. Also represented Merck in its venture capital-style investment in and its accompanying licensed spinoff of global IP rights for a regenerative monoclonal antibody known as “Sprifermin” to High Line Bio. or Merck, the agreements yield equity in High Line Bio (shares, plus an evergreen warrant), as well as cash payments via an upfront, milestones and royalties.
  • Representing Alnylam Pharmaceuticals in four patent infringement lawsuits filed in the District of Delaware against Moderna and Pfizer/BioNTech and their affiliates.


Goodwin’s life sciences team assist a diverse roster of pharmaceutical companies – both public and private – and life science venture capital firms. Mitchell Bloom and Kingsley Taft  jointly lead the team; Taft primarily advises life sciences companies throughout their life cycles on formation, venture financings, and IPOs, while Bloom is active in the biotechnology and medical IT spaces. Boston-based Robert Puopolo maintains a transactions focused practice, handling joint ventures and life sciences M&A. In San Francisco, Alexander Varond takes the lead on litigious matters concerning biosimilars and the Hatch-Waxman Act. Stuart Cable is particularly adept at advising on corporate governance and venture sourced investment, while Danielle Lauzon assists boards and management teams of therapeutics and bioscience companies. A large team including Philadelphia-based Rachael Bushey, who specializes in transactional and governance work in the pharma and biotech space, joined the firm from Troutman Pepper in January 2023. All named practitioners are based in Boston unless specified otherwise.

Practice head(s):

Mitchell Bloom; Kingsley Taft

Other key lawyers:

Stuart Cable; Kristin Havranek; Can Cui; Robert Puopolo; Alexander Varond; Danielle Lauzon; Rachael Bushey

Key clients

Amylyx Pharmaceuticals

Bain Capital Life Sciences


Blueprint Medicines

BioDelivery Sciences International

Checkmate Pharmaceutical

Forma Therapeutics

Global Blood Therapeutics

Scholar Rock

SpringWorks Therapeutics

Work highlights

  • Advised BioDelivery Sciences International in its definitive merger agreement to be acquired by Collegium Pharmaceutical for a total value of $604 million.
  • Advised Blueprint Medicines on its $1.25 billion strategic financing collaborations with Sixth Street and Royalty Pharma.
  • Advised Forma Therapeutics in its definitive agreement to be acquired by Novo Nordisk for $1.1 billion.

Hogan Lovells US LLP

Hogan Lovells US LLP houses a ‘highly knowledgeable and experienced‘ team of ‘real professionals with deep understanding', capable of advising on IP litigation and the IP aspects of life sciences M&A, in addition to FDA compliance issues. Working out of the Philadelphia office, Steve Abrams advises on all manner of capital markets transactions involving orphan drugs, oncology therapies, and pain products, while Blake Wilson assists with the approval and pre-market clearance of novel medical devices. Anishiya Abrol focuses on the commercialization of medical therapies, as well as in-licensing and out-licensing, while Lynn Mehler often negotiates REMS systems and advises on the scheduling of newly approved controlled substances. Baltimore-based Lauren Colton heads up the product liability side of the practice, working closely with high-profile clients such as John Hopkins and Bristol-Myers Squibb. Randy Prebula has ample experience assisting combination and medical device product manufacturers bringing new medical devices and technology to market, and David Fox is particularly adept at acting in matters concerning FDA and Hatch-Waxman regulation. Northern Virginia’s Cullen Taylor frequently advises international pharmaceutical and biotech companies on co-promotion, collaboration, and licensing agreements. All named practitioners are based in Washington DC, unless specified otherwise.

Practice head(s):

Steve Abrams; Lynn Mehler; Jane Summerfield; Randy Prebula; Lauren Colton; Cullen Taylor

Other key lawyers:

Anishiya Abrol; Blake Wilson; David Fox


‘Highly knowledgeable and experienced team. They are real professionals with deep understanding of the regulatory environment that allows creativity and out of the box thinking. Highly committed to their clients.

‘The team is very professional, knowledgeable and committed to the project. Things are always managed in a timely manner. The discussions are very efficient and the resulting materials are of the highest quality.’

Key clients

Baxter International Inc.

Bristol Myers Squibb


Exact Sciences


Jazz Pharmaceuticals




The University of Pennsylvania

Work highlights

  • Assisted CartiHeal with securing FDA pre-market approval for its Agili-C implant.
  • Advising Tessera Therapeutics on its IP needs, including patent prosecution, strategy, and transactional matters.
  • Advised PeproTech in its auction and subsequent US$1.85bn sale to Thermo Fisher Scientific.

King & Spalding LLP

The primarily Washington DC based practice at King & Spalding LLP, led by Mark Brown, Nikki Reeves, and Seth Lundy, consists of ‘creative lawyers' who handle both internal and government investigations, life sciences M&A, and fundraising matters. Reeves is known for her regulatory and FDA expertise, advising biologics and pharmaceutical companies on both pre and post-market compliance issues, good clinical practices, and good manufacturing practices. Brown assists biotech and medical device companies on FDA enforcement matters, and is particularly skilled at negotiating consent decrees of injunctions, while Lundy is well-versed in state and federal fraud and abuse issues. Lisa Dwyer maintains a digital health and regulatory focused practice, while Brian Bohnenkamp advises pharmaceutical companies on transparency laws imposed on manufacturers, including the Physician Payments Sunshine Act. John Shakow exhibits ‘extensive, almost encyclopedic expertise‘ across pharmaceutical government pricing, reporting, and Federal Supply Schedule matters, advising biotech entities on their interactions with the Department of Health and Human Services Office of Inspector General. Preeya Noronha Pinto has considerable  experience acting for life sciences manufacturers in reimbursement planning matters during product development.

Practice head(s):

Mark Brown; Nikki Reeves; Seth Lundy

Other key lawyers:

Laura Bushnell; Lisa Dwyer; Brian Bohnenkamp; John Shakow; Mark Jensen; Preeya Noronha Pinto


‘The team consists of creative lawyers who focus on solving issues. They are willing to provide direct opinions and views.’

‘John Shakow is a highly effective communicator with a willingness to provide a direct assessment and opinion. John has extensive, almost encyclopedic expertise in government pricing programs.’

Key clients


Acadia Pharmaceuticals

Allergan, Inc.

Amarin Corporation

Amryt Pharmaceuticals

Baxter International


Bristol Myers Squibb

Carl Zeiss Vision

Coloplast Corporation

Eli Lilly

EMD Serono

Exact Sciences


HeartFlow, Inc.


Hope Medical Enterprises, Inc. d/b/a/ Hope Pharmaceuticals

Imperative Care

Integra LifeSciences

Invacare Corporation


LEO Pharma, Inc.


Novo Nordisk




PolarityTE, Inc.


Takeda Pharmaceuticals

Teleflex, Inc.


Zimmer Biomet

Work highlights

  • Advised on all FDA regulatory aspects of a $2.4 billion merger between Oaktree Acquisition Corp. II. and Alvotech.
  • Represented Walmart in a nation-wide litigation involving allegations that retailers of private-labeled acetaminophen failed to warn pregnant mothers about the potential risks to their children of prenatal exposure.
  • Acted for Eisai Pharmaceuticals in several rounds of negotiations regarding its multi-billion-dollar research and development collaboration with Biogen, formed to co-develop products to prevent and treat Alzheimer’s disease.

Ropes & Gray LLP

The team at Ropes & Gray LLP provides a diverse offering to biotech startups, biopharmaceutical companies, and private equity investors. The practice handles the full gamut of issues concerning IP asset protection, and research funding. Marc Rubenstein and Michael Beauvais jointly lead the Boston based group. Rubenstein frequently represents pharmaceutical, biotech, and medical device corporates in private securities offerings; while Christopher Comeau acts for investors and public companies in minority investment transactions and private mergers within the medical tech industry. Kellie Combs continues to assist biotech companies with regulatory and compliance issues.

Practice head(s):

Marc Rubenstein; Michael Beauvais

Other key lawyers:

Chris Comeau; Megan Baca; Arthur Mok; Alyce Chen; Brad Flint; Geoffrey Lin; Gregory Levine

Key clients

Becton, Dickinson and Company

Sana Biotechnology

CJ CheilJedang Corp.

Medtronic plc

Becton, Dickinson and Company

Sana Biotechnology

CJ CheilJedang Corp.

Medtronic plc

Becton, Dickinson and Company

Sana Biotechnology

CJ CheilJedang Corp.

Medtronic plc

Becton, Dickinson and Company

Sana Biotechnology

CJ CheilJedang Corp.

Medtronic plc

Becton, Dickinson and Company

Sana Biotechnology

Work highlights

  • Represented Pfizer in its acquisition of Biohaven Pharmaceuticals, Arena Pharmaceuticals, and Trillium Therapeutics, for an aggregate of over $20bn.
  • Represented Acceleron Pharma in its $11.5 billion sale to Merck & Co..
  • Represented Ionis Pharmaceuticals in its $3.5 billion collaboration with AstraZeneca.

Dechert LLP

Regarded by some clients as ‘easily the best', Dechert LLP’s global life sciences practice often handles patent and IP litigations, contentious antitrust matters, and product liability related issues. Working with a host of start-ups and mature pharmaceutical and biotech companies, Andrea Reid co-heads the team from Boston, drawing on her expertise in IP strategy and prosecution. Based in New York, the ‘truly exceptional‘ fellow co-chair David S Rosenthal maintains a corporate finance and life sciences M&A focused practice. Rosenthal routinely advises public and private investment banks and venture capital firms on IPOs and CMPOs looking to invest in life sciences and medical device companies. Also based in New York, Katherine Helm notably acts for biotech and pharmaceutical companies in biologics patent disputes before the PTAB.

Practice head(s):

Andrea Reid; David S. Rosenthal

Other key lawyers:

Melanie Thill-Tayara; Katherine Helm


‘The quality, competence, and knowledge of the firm is without peer, Dechert is easily the best. They pay attention to detail and are rigorous in all of their reviews.’

‘The team has a rapid grasp of technical issues and is incredibly supportive. I would strongly recommend them to anyone seeking their legal assistance in any matters relating to healthcare.’

‘David Rosenthal truly stands out in his field. He carefully researches matters of relevance, and is empathetic. He is a truly exceptional person.’

Key clients

Aquestive Therapeutics


BioDelivery Sciences


Cerus Endovascular

Chiesi Pharmaceutical

CVS / Aetna

Eli Lilly and Company

Endo Pharmaceuticals

Flo Health


Homology Medicines

Johnson & Johnson

Moderna Therapeutics

Nimbus Therapeutics

Pfizer / Viatris

Purdue Pharma

Third Harmonic Bio

Quest Diagnostics

Work highlights

  • Represented Eli Lilly & Co. in cases relating to their worldwide discovery authorized under 28 U.S.C § 1782, in a global patent litigation involving Novartis.
  • Advising Cerus Endovascular on its (up to) US$525 million purchase agreement to be acquired by Stryker Corporation.
  • Advised AVEO Oncology on its US$566 million definitive agreement with LG Chem to acquire AVEO for $15.00 per share, providing patent strategy and IP diligence.

DLA Piper LLP (US)

The ‘top-notch, best-in-class‘ practice at DLA Piper LLP (US) handles a diverse range of mandates, including Hatch-Waxman suits, supply agreements, and drug pricing and market access matters. Matthew Holian and Andy Gilbert jointly head the practice from Boston and New Jersey, respectively. Holian assists medical device and pharmaceutical corporates with compliance investigations and defends clients against claims from patients in clinical trials, while Gilbert dispenses advice to life sciences companies on corporate financing, licensing, and M&A. In the New York office, Loren Brown, rated by clients as an ‘internationally known and respected litigator', heads the disputes practice, frequently leading mass-tort actions for multinational life sciences companies including Pfizer, Novo Nordisk, and Honeywell. Katie Insogna works out of the Boston office, handling all matters concerning the defense of medical device and pharmaceutical companies in product liability litigations, while New York-based 'top-tier attorneyLucas Przymusinski handles drug and device litigations, product safety-issues, and recalls.

Practice head(s):

Matt Holian; Andy Gilbert

Other key lawyers:

Loren Brown; Katie Insogna; Chris Strongoski; Lucas Przymusinski; Geoffrey Levitt


‘DLA Piper has built a wing-to-wing platform to service at the highest professional level. They bring sophisticated and varied professional experiences as a coordinated team. They climb into the boat with their clients to help steer and guide them through the most difficult legal and business challenges.’

‘They are subject matter experts with broad and varied experiences that gives them a larger perspective and allows them to think more creatively and strategically.’

‘DLA has a top-notch, best-in-class life sciences practice. The firm has industry leaders who take a strategic and proactive approach to managing both pre-litigation assessments as well as litigation response, with exceptional results.’

‘Loren Brown is the pre-eminent leader and authority in the life-sciences area (pharmaceuticals and biotechnology) and is an internationally known and respected litigator, and an advisor of the highest caliber.’

‘Lucas Przymusinski is a top-tier attorney and medical doctor whose knowledge of science and medical aspects of a case is at the cutting edge of the industry. He is a trusted advisor for clients.’

‘They are absolutely extraordinary. They stand out due to their level of technical knowledge combined with nuanced understanding.’

Key clients

Sanofi S.A.

Sanofi-Aventis US LLC

Sanofi-Aventis Recherche and Development

Pfizer Inc.

Johnson & Johnson



Bristol-Myers Squibb


Novo Nordisk

Aclaris Therapeutics


Work highlights

  • Advising Sanofi on litigation and regulatory issues relating to Zantac.  The litigation consists of an MDL proceeding formed in February 2020 and pending in the US District Court for the Southern District of Florida, with tens of thousands of other lawsuits pending in a dozen state courts.
  • Advising Intercept Pharmaceuticals, Inc. on a deal to sublicense to Advanz Pharma the rights to commercialize Ocaliva® outside of the US and sell certain foreign subsidiaries and rights regarding Intercept’s international operations. The deal is valued at up to US$450 million.
  • Representing Harbour BioMed and related licensors/licensees of US patents covering the genetic engineering of transgenic animals to manufacture therapeutic heavy chain-only monoclonal antibodies. The firm investigated and brought suit against US-based infringer Teneobio.

Mayer Brown

Mayer Brown’s ‘very creative and smart' New York-based team represents a spread of biotech, device, and pharmaceutical companies, as well as a number of investment banks. Lisa Ferri heads the practice alongside Reb Wheeler. Wheeler primarily assists financial institutions and private equity firms on licensing, collaboration, and joint venture-related matters, while Ferri often appears before the ITC and PTAB in patent challenges under the Biologics Price Competition and Innovation Act (BPCIA). Anna Pinedo, who heads up the practice's capital markets offering, possesses key experience advising on securities and derivatives.

Practice head(s):

Lisa Ferri; Reb Wheeler

Other key lawyers:

Anna Pinedo; David Carpenter


‘Very creative and smart.’

‘This team is, at its core, collaborative and transparent.’

‘The team is essential in risk management and providing the resources necessary for decision-making.’

Key clients

Gilead Sciences

Sanofi S.A.


Beckton Dickinson

Johnson & Johnson

Galderma S.A.

Abbott Labs

Avego Healthcare Partners

Nestlé Health Science


Boston Scientific Corporation

Saol Therapeutics Inc.


Roivant Sciences


Alexion Pharmaceuticals, Inc.

Protalix Biotherapeutics, Inc.

HemoSonics, LLC (Diagnostica Stago S.A.S)

Galderma Laboratories, L.P.

Opiant Pharmaceuticals, Inc.

Endo Health Solutions / Endo Pharmaceutical Inc. / Par Pharmaceutical Inc.

Work highlights

  • Represented Saol Therapeutics in its sale of a portfolio of four marketed plasma-derived hyperimmune products to Kamada Ltd., an Israel-based biopharmaceutical company.
  • Represented Gilead Sciences as lead IP counsel in the $405 million acquisition of MiroBio, a UK biotechnology company.
  • Represented Nestlé Health Science in a licensing and collaboration transaction with Seres Therapeutics to jointly commercialize Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection in the US and Canada.

Morrison Foerster

The ‘highly collaborative, diverse and exceptionally skilled' team at Morrison Foerster represents a number of international pharmaceutical companies and emerging biotech players. Practice head Michael Ward, who divides his time between San Francisco and Boston, has a great deal of experience in managing IP portfolios. California based practitioner Catherine Polizzi utilizes her ‘exceptional‘ knowledge of biopharmaceutical technology to advise on IP portfolio development and acquisitions. Also based in California, Janet Xiao - praised by clients as being a ‘creative, deep‘ thinker - focuses on cross-border transactions between the US and China, primarily advising biopharmaceutical companies.

Practice head(s):

Michael Ward

Other key lawyers:

Catherine Polizzi; Janet Xiao; Stacy Cline Amin; Lisa Silverman


‘The team is highly collaborative, diverse and exceptionally skilled. I have never encountered an oversized ego here. The firm approaches every matter they handle thoughtfully and seriously.’

‘Catherine Polizzi is exceptional in her knowledge of complicated biopharmaceutical technologies, patent law and the value of intellectual property to the biopharmaceutical industry.’

‘Janet Xiao is always on top of the detail, and her advice is commercial, always on time and rigorous in its analysis.’

‘Besides producing great work, the life science practice is communicative and easy to work with.’

‘Janet Xiao and her team are excellent. Everything runs very smoothly and thoroughly under Janet’s command. She understands the industry, and she and her team are creative, deep thinkers.’

‘The team is collaborative, curious, and have relevant technology area experience. I have confidence that the team can competently handle IP matters ranging from a variety of technologies.’

Key clients

10x Genomics


Abraxis Bioscience

Alpine Immune Sciences



AllyBridge Group


Bluesphere Bio

Bard (f/k/a C.R. Bard)

Carlsmed, Inc.


CSPC Pharmaceutical Group

Cartography Biosciences

CG Oncology, Inc.

Cornell University

DNA Genotek; OraSure Technologies, Inc

Dewpoint Therapeutics

Eureka Therapeutics, Inc.

Evolve Biosystems

Foundation for Food & Agriculture Research


iPharma Limited

Johnson & Johnson

Kindred Biosciences

McKesson Corporation



Orbimed Advisors


Praxis BioTech LLC

Pillar Biosciences

Rakuten Medical

Sequlite Genomics


Santen Pharmaceuticals



Triastek, Inc.

Work highlights

  • Advised Chugai Pharmaceutical Co. on securing a USD$775 million patent litigation settlement. The case concerned Chugai’s patented recycling antibody technology and Alexion’s accused product, ravulizumab, which is marketed by Alexion as ULTOMIRIS.
  • Represented Seagen Inc. in a patent infringement trial in the Eastern District of Texas against global pharmaceutical company Daiichi Sankyo Co. Ltd.
  • Advised Genentech on the development of the company’s strategy for its multi-billion-dollar portfolios. The firm also led several matters that have allowed Genentech to obtain patent-term extensions for its key drugs.

Paul Hastings LLP

The life sciences and healthcare team at Paul Hastings LLP assists clients with patent infringement actions and patent enforcements. Practice head Gary Giampetruzzi routinely conducts internal investigations concerning off-label promotion, anti-kickback, and specialty pharmacies, while Eric Dittmann is especially experienced in Hatch-Waxman and patent litigations, and appeals. Bruce Wexler maintains an IP-focused practice, advising range of mid-size start-ups and small biotech companies, in addition to well known global corporates. California-based practitioner Jeff Hartlin handles corporate and M&A mandates for clients in the public and private biotech, medical device, and biopharmaceutical sectors. All named practitioners are based in New York unless specified otherwise.

Practice head(s):

Gary Giampetruzzi

Other key lawyers:

Bruce Wexler; Eric Dittmann; Nathan Sheers; Jeff Hartlin; Peter Lindsay


‘Very close, senior partner level engagement throughout the firm. I always feel like a top priority client.’

‘Peter Lindsay and Nathan Sheers provide very sound advice, giving examples based on their volume of experience. Where they need to follow up, they are always quick to do so.’

Key clients


Mitsubishi Tanabe Pharma Corporation

Daiichi Sankyo Co., Ltd.

L’Oréal USA, Inc. and L’Oréal S.A.

Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company

AbbVie Inc. and Allergan, Inc.


Alpha Teknova, Inc.

Masimo LHC Limited

Adamis Pharmaceuticals Corporation

Merck & Co., Inc. and Eisai R&D Management Co., Ltd.

Otsuka Pharmaceutical Co., Ltd.

SD Biosensor and SJL Partners

Scilex Holding Company

Work highlights

  • Advising BioNTech, in collaboration with its business partner Pfizer, as it deals with patent disputes concerning numerous participants in the mRNA and lipid nanoparticle formulation space, in connection with the launch of its Covid-19 vaccine.
  • Representing Daiichi Sankyo in a commercial dispute with Seagen Inc. concerning Daiichi Sankyo’s biotech drugs. Daiichi was awarded a complete victory in the arbitration.
  • Advised Scilex Holding Company, a Sorrento Therapeutics majority-owned subsidiary, in its agreement to merge with Vickers Vantage Corp. I (VCKA), a special purpose acquisition company. Pro forma equity value post-money of approximately $1.64 billion.

Weil, Gotshal & Manges LLP

Working across offices in New York and California, the team at Weil, Gotshal & Manges LLP has a ‘wide and deep knowledge’ of life sciences related antitrust, IP, and M&A matters. The team often advises biotech, medical devices, and pharmaceutical companies on licensing agreements, commercial litigations, and false advertising issues. Edward Reines co-heads the practice from Silicon Valley, contributing his broad knowledge of willful patent infringement and contentious IP issues, while New York-based co-head Elizabeth Weiswasser is known for her focus on life science patent litigation, often appearing before the PRAB and ITC for pharmaceutical companies. Jeffrey Osterman and Charan Sandhu jointly lead the technology and IP transactions practice from New York, leveraging their expertise in joint developing agreements, strategic alliances, and technology transfer agreements. Based in Silicon Valley, Derek Walter is noted for his life sciences IP litigation capabilities.

Practice head(s):

Edward Reines; Elizabeth Weiswasser

Other key lawyers:

Jeffrey Osterman; Charan Sandhu; Derek Walter


‘The team knows the industry and understands the technology. They have a wide and deep knowledge base which sets them apart from other firms.

The team is good across the board, from associates to senior partners.’

‘They have knowledge of the industry, technology, and industry players. They are extremely responsive and business-savvy in their advice.’

Key clients


Johnson & Johnson







Bio-Rad Laboratories

Pacific Biosciences

Work highlights

  • Acted for CareDx in securing a $45m false advertising jury verdict against Natera, including punitive damages.
  • Acted for Illumina in securing a major jury verdict of willful patent infringement in a competitor patent dispute against Chinese conglomerate BGI, as well as a permanent injunction extending the preliminary injunction we earlier secured that halted BGI’s planned, billion-dollar U.S. launch of its competing DNA sequencers in 2020.
  • Acted for Regeneron in securing a decision from the PTAB in their favor, protecting best-in-class novel biologic to treat macular degeneration and other serious eye diseases.


WilmerHale’s primarily Boston-based team advises a range of clients, including diagnostic and medical device corporates, universities and research institutions, and investment banks. Practice co-chair Stuart Falber advises a range of public life science companies on capital markets related matters, while fellow co-chair Lisa Pirozzolo acts in Hatch-Waxman cases and licensing disputes, often appearing before the ITC and the PTAB. Based in New York, David Bassett has an IP litigation focused practice, and often contends with biotech and pharmaceutical patent disputes alongside Robert Gunther, who also handles trade secret cases before arbitration tribunals. Sarah Hogan focuses on the life sciences and digital health industries, and has a great deal of experience in the negotiation of IP licenses and strategic collaborations.

Practice head(s):

Stuart Falber; Lisa Pirozzolo

Other key lawyers:

David Bassett; Robert Gunther; Sarah Hogan; Craig Hilts

Key clients

Becton Dickinson and Company

Biogen International GmbH

Emergent BioSolutions

Exelixis, Inc.

Gilead Sciences

Inozyme Pharmaceuticals

Iterum Therapeutics



Reckitt Benckiser Group

Work highlights

  • Advised Beam Therapeutics on its exclusive, four-year research collaboration with Pfizer, for up to $1.35 billion.
  • Represented Bristol-Myers Squibb Company (BMS) where the Federal Circuit affirmed a post-trial decision holding that the patents covering BMS’s Eliquis® are valid and infringed by all generics challenging them.
  • Advised Mersana Therapeutics on its $1.36 billion global collaboration agreement with GSK.

Debevoise & Plimpton LLP

The chiefly New York-based team at Debevoise & Plimpton LLP assist clients with the full spectrum of corporate healthcare and life sciences matters, including regulatory compliance on transactions and divestitures, and cases involving fraud and unjust enrichment claims. Mark Goodman handles commercial disputes and government investigations alongside Maura Monaghan. Kevin Rinker handles a number of life sciences M&A deals and private equity buyouts, while Andrew Bab focuses on corporate and private equity related matters, bolstered by Jennifer Chu. Washington DC’s Paul Rubin, who heads the FDA regulatory side of the practice, often advises private equity funds on transactions involving life sciences entities.

Practice head(s):

Andrew Bab; Mark Goodman; Maura Monaghan; Kevin Rinker; Paul Rubin

Other key lawyers:

Jennifer Chu

Key clients



Certain former directors and shareholders of Purdue Pharma, Inc.

Clayton, Dubilier & Rice, LLC

Ellodi Pharmaceuticals


Former CEO of Sandoz, Armando Kellum

Hospital Corporation of America and subsidiaries

Johnson & Johnson

J.P. Morgan Securities

JAB Holdings

Merck KGaA

TPG Capital

Work highlights

Fenwick & West LLP

The team at Fenwick & West LLP serves a varied client base of public and private research institutions and life sciences companies in the microbiome-based therapeutics, immuno-oncology, and precision medicine fields. The practice routinely handles financing rounds for life sciences startups, trade secret disputes, and issuer side pharmacy IPOs. Both based on the west coast, practice co-head Matthew Rossiter is adept at public and private financings, while fellow practice co-head Stefano Quintini focuses on tech transactions in the healthcare and pharmaceutical spaces. Seattle’s Melanie Mayer acts as co-head, utilizing her prior expertise in molecular biology and genetics to act in IP litigation, and licensing and patent infringement disputes concerning enzyme variants, drug screening, and polymers. Robert Freedman maintains a capital markets focused practice, regularly advising biopharmaceutical companies. Effie Toshav, who divides her time between San Francisco and Seattle, handles the full range of life science transactions. Carl Morales joined the team from Dechert, contributing his expertise in loss of exclusivity for biologic drugs.

Practice head(s):

Matthew Rossiter; Melanie Mayer; Stefano Quintini

Other key lawyers:

Robert Freedman; Amanda Rose; Effie Toshav; Jake Handy; James Trainor; Jeffrey Oelke; Robert Counihan

Key clients



Amyndas Pharmaceuticals


Day One Biopharmaceuticals

Incyte Corporation and Calithera Biosciences

Marshall Wace

Maze Therapeutics

Meril Life Sciences Pvt. Ltd. and Meril, Inc.


Morphic Holding, Inc.

Mythic Therapeutics

Novo Nordisk

Pharmacosmos A/S

ProThera Therapeutics

Royalty Pharma

Quest Diagnostics Investments

Scribe Therapeutics


Sutro Biopharma


Third Harmonic Bio, Inc.

T-knife Therapeutics

TRexBio Inc.

Work highlights

  • Represented Amunix in its $1.2 billion acquisition by Sanofi.
  • Representing Novo Nordisk A/S and Novo Nordisk Inc. in Hatch-Waxman patent litigation arising from ANDAs filed with the FDA, seeking approval to market generic versions of Novo Nordisk’s GLP-1 diabetes treatment, Ozempic®.
  • Represented Third Harmonic Bio, Inc. in its initial public offering of 12,535,000 shares of common stock.

Foley Hoag LLP

Foaley Hoag’s life sciences team advises medical device and biotech clients on a variety of corporate, commercial, and patent related life sciences mandates, including venture financing, tax planning, and trademark disputes. Boston based practice co-head Hemmie Chang advises on strategic alliances and IP transactions, while co-head Jeffrey Quillen regularly acts for emerging biotech companies, research universities, and pharmaceutical companies with patent licensing agreements. John Harre handles strategic collaborations for medical device companies, and IP practitioner Hathaway Russell assists biotech start-up companies and pharmaceutical companies with patent portfolio management, particularly in relation to pharmacogenomics and disease biomarkers. John Gourary and Rachel Beller joined the New York practice from Covington & Burling in October 2022, contributing their expertise in the financing of pharmaceutical royalty streams.

Practice head(s):

Hemmie Chang; Jeffrey Quillen

Other key lawyers:

Bryant Godfrey; John Harre; Hathaway Russell

Key clients

AbbVie, Inc.

AffaMed Therapeutics

Amgen Inc.

Becton, Dickinson (BD)


Biogen Inc.

Dana-Farber Cancer Institute

Dicerna Pharmaceuticals

Gilead Sciences, Inc.

Ginkgo Bioworks

Harvard University

H.I.G. BioHealth Partners

La Jolla Pharmaceuticals

LegoChem Biosciences, Inc.

Myriad Genetics, Inc.

Organogenesis Inc.

Pear Therapeutics

Roche Diagnostics

Thermo Fisher Scientific

University of California

Work highlights

  • Represented MDxHealth, a commercial-stage precision diagnostics company, in its $100 million acquisition of Genomic Health, a subsidiary of Exact Sciences.
  • Acted for Enanta in a lawsuit in the District of Massachusetts, asserting that Pfizer Inc.’s Paxlovid™ infringes an Enanta patent that issued earlier that month, based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by its scientists.
  • Represented BostonGene in connection with its $150 million Series B financing.

Gibson, Dunn & Crutcher LLP

The life sciences team at Gibson, Dunn & Crutcher LLP advises a diverse client roster of life sciences and investment companies, including Gilead Sciences, the Dana-Farber Cancer Institute, and Amyris. Jane Love leads the team alongside Ryan Murr, working from New York and San Francisco, respectively. Love routinely acts in patent litigations concerning biologics, RNA therapies, and therapeutic nucleic acids, while Murr advises investors targeting the medical device and diagnostics, biotech, and pharmaceutical industries on securities offerings and licensing transactions. Working out of the San Francisco office, Brandon Berns assists clients with corporate transactional matters, while of counsel Todd Trattner works with research institutes, diagnostics companies, and biotech companies – both public and private – on IP transactions. Charlotte Jacobsen joined the New York practice from Ropes & Gray LLP in April 2022, contributing her experience in handling chemical and biotech patent and licensing disputes, often appearing before the PTAB, AAA, and ICC.

Practice head(s):

Jane Love; Ryan Murr

Other key lawyers:

Charlotte Jacobsen; Brandon Berns; Todd Trattner

Key clients

Gilead Sciences

Dental Monitoring


EMD Serono and Pfizer

Novartis Pharmaceuticals and Dana-Farber Cancer Institute

Guardant Health




Royalty Pharma

Selecta Biosciences

General Electric Healthcare Life Sciences

Arrowhead Pharmaceuticals

Ultragenyx Pharmaceutical

BioCryst Pharmaceuticals

MoonLake Immunotherapeutics AG

HealthCare Royalty Partners

Work highlights

Greenberg Traurig, LLP

Led by the ‘simply terrificDavid Dykeman in Boston and Wayne Elowe in Atlanta, the ‘enormously supportive, collaborative, strategic, and insightful‘ team at Greenberg Traurig LLP handles a diverse range of mandates concerning immunology, drug delivery, and clinical trials. The practice serves a diverse range of clients, including Embecta Corp., GrandPharma China, and Teva Pharmaceuticals. Dykeman routinely research institutions on the IP aspects of life science M&A, venture capital investments, and licensing matters, while Elowe maintains a corporate focused practice, primarily acting for clients in commercial transactions. Atlanta’s Lori G. Cohen is an experienced litigator who handles product liability and mass tort disputes. In the Boston office, the ‘exceptionalRoman Fayerberg assists clients with the management and development of global patent portfolios, issues surrounding freedom to operate, and patent validity matters; and Melissa Hunter-Ensor represents biotech, diagnostics, and medical device companies in strategic alliances and patent disputes.

Practice head(s):

David Dykeman; Wayne Elowe

Other key lawyers:

Lori Cohen; Roman Fayerberg; Melissa Hunter-Ensor; Barry Schindler


‘Greenberg Traurig is enormously supportive, collaborative, strategic, and insightful. One specific attribute that is extremely valuable is their understanding of the capabilities, and financial resources of their clients.’

‘They offer exceptional customer service, and perform insightful landscape assessments and counselling on global patent prosecution.’

‘David Dykeman and Roman Fayerberg are simply terrific. They are exceptional at their trade and understand the pressures placed on small companies. They both are exceptionally responsive, understanding and insightful. Their supporting team deserves tremendous accolades as well. I wholeheartedly recommend these two attorneys to anyone seeking partners and collaborators for the strategic guidance and prosecution of their IP.’

Key clients

Embecta Corp.

Huadong Medicine Co., Ltd.

GrandPharma China

OTR Acquisition Corp.

Teva Pharmaceuticals

Elios Vision

Provention Bio, Inc.

Aspira Women’s Health (formerly Vermillion)

PAVMed, Inc.

Lucid Diagnostics

Exactech, Inc.

RedHill Biopharma

Work highlights

  • Advising Embecta on the development and management of Embecta’s worldwide IP portfolio, including over 2000 patents and trademarks.
  • Represented Huadong Medicine Co., Ltd. in two licensing deals. Huadong Medicine is a large pharmaceutical company in China with a focus on oncology and Antibody-drug Conjugates research, development, and commercialization.
  • Advised Redhill Biopharma on obtaining key patents for pipeline products. The firm also represents Redhill in connection with the management of its worldwide trademark portfolio and handling trademark disputes.

Kirkland & Ellis LLP

Regarded by clients as ‘outstanding in every aspect of their practice', the biotechnology, pharmaceutical, and life sciences practice at Kirkland & Ellis LLP advises private equity and venture capital investors, as well as biotech and pharmaceutical companies, at varying stages of development. New York based litigator Jay Lefkowitz often acts in pharmaceutical antitrust suits, FCA and FDA related internal investigations, and product liability cases. Chicago’s ‘absolutely brilliantJim Hurst is a litigator who handles commercial, IP and patent disputes, while New York’s ‘highly experienced, highly skilled and talentedPatricia Carson is a life sciences litigator who focuses on patent strategy and disputes, often acting for biotech, chemical, and pharmaceutical companies.

Other key lawyers:

Jay Lefkowitz; Matt Rowen; Jim Hurst; Patricia Carson; Jeanna Wacker


‘Excellent biopharma litigation practice (including drafting of settlement agreements), one of the best teams I have had a chance to work with.

‘Whether it be their skills, competence, experience as litigators, knowledge of the industry, or knowledge of the technology, the Kirkland team is absolutely top of the cream. One cannot single out one aspect of their practice which is outstanding. The Kirkland team is outstanding in every aspect of their practice.’

‘Jeanna Wacker is one of the most talented, competent, professional, dedicated, skilled outside counsel I have ever worked with. Jeanna is fantastic and will make sure to provide you with the best legal advice and litigation support available.’

‘Jim Hurst’s experience and skills as a trial lawyer are stunning. Absolutely brilliant.’

‘Patricia Carson is very knowledgeable of the industry and technology, highly experienced, highly skilled and talented.’

Key clients

Abbott Laboratories

Abbvie Inc.

Actavis Generics

Akorn, Inc.

Albertson Companies, Inc.

Allergan plc

Amneal Pharmaceuticals Inc.

Arya Sciences Acquisition Corp. II

Association for Accessible Medicines

Barr Phamaceuticals

Bristol-Myers Squibb Co.


Cephalon Inc.

Danaher Corp.

Eagle Pharmaceuticals Inc.

Glaxosmithkline plc

Hospira Inc.

Impax Laboratories

Lannett Co.

Lupin Ltd.

Sun Pharmaceuticals Industries Ltd.

Teva Pharmaceuticals

Torrent Pharmaceuticals Ltd.

Upsher-Smith Laboratories LLC

Work highlights

Norton Rose Fulbright

Norton Rose Fulbright’s team advises biotech and bioscience companies, and retail pharmacies on routine merger clearances, ITC proceedings, and claims arising from data security breaches and privacy violations. D’Lesli M. Davis leads the team from Dallas alongside Jonathan B. Skidmore. Davis acts as trial counsel on behalf of medical device and pharmaceutical clients in mass tort cases and product liability litigation, while Skidmore handles a broad range of issues including drug safety, marketing, and discoveries. In the New York office, David Kessler heads the domestic data and information risk practice, advising clients on safe data storage and the integration of record retention. Also based in New York, Robin Adelstein acts as the US head for antitrust and competition at the firm, routinely assisting life sciences and pharmaceutical companies on M&A, trade association activities, and government investigations.

Practice head(s):

D’Lesli M. Davis; Jonathan B. Skidmore

Other key lawyers:

David Kessler; Robin Adelstein; Debbi Johnstone

Key clients



Neptune Wellness Solutions Inc.

Valeant Pharmaceuticals North America LLC (Bausch Health US, LLC)

Valeant Pharmaceuticals International (Bausch Health Americas, Inc.)

Oceanside Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)

CVS Pharmacy, Inc.

Human Power of N Company (HumanN)

Work highlights

  • Representing Valeant Pharmaceutical, now known as Bausch Health, in the Generic Pharmaceuticals Pricing Antitrust litigation.
  • Representing CVS Pharmacy, Inc. over claims regarding the alleged illegal sale of homeopathic drug products in violation of the Federal Food, Drug & Cosmetic Act.
  • Representing McKesson in the Sartan MDL, a multi-district litigation against all levels of the supply chain.

O'Melveny & Myers LLP

O'Melveny & Myers LLP’s life sciences industry group assists a number of high-profile clients, notably AstraZeneca, Novartis, and AbbVie. Steve Brody, who co-leads the team from the Washington DC, is a litigator who focuses on class actions, government investigations, and mass torts, regularly assisting clients with medical device promotional issues. Lisa Pensabene co-heads the practice from New York alongside Ross Galin. Galin advises medical device and pharmaceutical companies and their executives on compliance, FCA litigation, and government enforcement actions, while Pensabene specializes in pharmaceutical patent litigation concerning biologics. Also based in New York, Hassen Sayeed utilizes his medical background to act in cases regarding the Hatch-Waxman and Biologics Price Competition and Innovation Act. San Francisco based practice co-chair Scott Elliott maintains a corporate and transactions focused practice.

Practice head(s):

Steve Brody; Lisa Pensabene; Ross Galin; Scott Elliott

Other key lawyers:

Hassen Sayeed

Key clients


Amgen, Inc.


C.R. Bard, Inc

Endo Pharmaceuticals

Johnson & Johnson

Novartis Pharmaceuticals Corporation

Par Pharmaceutical

Progenics Pharmaceuticals, Inc.

ViiV Healthcare

Work highlights

  • Represented Johnson & Johnson in opioids trials, reversing, on appeal, a multi-million-dollar verdict against the client and defeating a cross-appeal that sought more than US$9 billion.
  • Acted for Johnson & Johnson in claims at trial against Los Angeles, Orange, and Santa Clara Counties and the city of Oakland, which sought $50 billion from the client and other defendants on the alleged grounds that pharmaceutical manufacturers violated public-nuisance laws by causing an opioid epidemic through misleading marketing and promotion of their medications.
  • Acted for Becton Dickinson subsidiary C.R. Bard, defeating an antitrust tying case brought by Bard’s competitor, AngioDynamics, involving a vascular catheter device known as a PICC.

Orrick, Herrington & Sutcliffe LLP

The team at Orrick, Herrington & Sutcliffe LLP is well equipped to assist clients with the full spectrum of life science mandates spanning the digital health, research, biotech, and pharmaceutical industries. Stephen Thau co-heads the practice from New York, regularly advising bioscience companies on the sales of their portfolios, and series financings for medical device companies. Washington DC-based co-chair Thora Johnson focuses keenly on health information privacy; she often assists health IT vendors with the setting up and operation of cyber security programs, and the permitted use and disclosure of health information for innovation. Also based in Washington DC, Anne Murray advises international medical device manufacturers on SEC and DOJ declination letters, and routinely represents clients in both government and internal investigations.

Practice head(s):

Stephen Thau; Thora Johnson

Other key lawyers:

Anne Murray; Gargi Talukder

Key clients


Catalyst Biosciences

Volastra Therapeutics

64-X Bio

Kite Pharma, Inc.

Medical Microinstruments, Inc.

Ferring International Center SA

Aledade, Inc.

Sosei Heptares



SOC Telemed Inc.

Work highlights

  • Advised Bayer on its three-year strategic partnership with biotech company Ginkgo Bioworks to develop biological solutions in areas such as nitrogen optimization, carbon sequestration, and next generation crop protection. In addition to the partnership, the transaction included the divestment of Bayer’s West Sacramento Biologics Research & Development site and its internal discovery and lead optimization platform to Ginkgo Bioworks for $83 million.
  • Representing Kite Pharma, Inc. in an appeal involving a huge patent-infringement verdict against the lifesaving cancer therapy of the client.dan The jury agreed and awarded US$780 million. The judge enhanced the jury verdict by 50%, increasing the judgment to US$1.2 billion.
  • Advised Medical Microinstruments, Inc. (MMI) in its US$75 million Series B financing.

Proskauer Rose LLP

Proskauer Rose LLP provides a diverse offering for clients seeking advice on FDA regulation and patent prosecution. Boston-based practice head Fangli Chen assists clients with patent portfolio management to protect biochemical, immunology, and diagnostics products. New York’s Daryn Grossman acts as the managing partner of the firm, while practice co-head Siegmund Gutman - based in Los Angeles - is an accomplished litigator who acts for biotech, biologics, and medical device clients in disputes concerning biosimilars and Hatch-Waxman legislation. New York based Robert Cantone maintains a corporate-focused practice, advising on life sciences M&A, strategic alliances, and corporate governance.

Practice head(s):

Fangli Chen; Daryn Grossman; Siegmund Gutman

Other key lawyers:

Robert Cantone

Key clients


Sanofi Pasteur Inc.


Gilead Sciences



NuVasive, Inc.

Versicolor Technologies


Zion Pharma

Translate Bio

Various Life Sciences Companies

ARCH Venture Partners


ARCH Venture Partners

Third Rock Ventures

Telegraph Hill Partners

Mass General Brigham Ventures

Valeant Pharmaceuticals International Inc. (now known as Bausch Health)

Lupin Pharmaceuticals

Work highlights

Baker Botts L.L.P.

The IP and life sciences team at Baker Botts L.L.P. serves a broad client base consisting of biotech, medtech, and pharmaceutical companies. Working in close collaboration with the litigation and antitrust departments, the team dispenses ‘outstanding tactical advice’ on drug price fixing cases, class actions, and evaluations of third party IP rights. Steve Lendaris leads the practice from New York, assisting clients with biotech IP issues, product launches, and the development of patent filing strategies. San Francisco’s Michael Torosian advises emerging companies and investors on venture capital financings and IPOs, while William Lavery supports the team from Washington DC, drawing on his expertise in government investigations and antitrust litigation. Stephen Hash and Margaret Sampson left the practice in July 2022. Courtney Fore left the firm for an in-house position in May 2022.

Practice head(s):

Steve Lendaris

Other key lawyers:

Michael Torosian; William Lavery; Christopher Wilson


‘Provides outstanding tactical advice and defends our company in significant and material litigation.’

‘Christopher Wilson is smart, hard-working, and provides advice. He is tactical, and strategic in the defense of his clients.’

Key clients



Novartis International AG

Sandoz Inc.

Merck & Co., Inc.

Oxford Nanopore Technologies

Eikon Therapeutics, Inc.

Fujifilm Holdings Corporation

Editas Medicine

Assertio Therapeutics

Memorial Sloan Kettering Cancer Center

UnitedHealth Group Incorporated

UnitedHealthCare, Inc.

Optum, Inc.

Lyell Immunopharma

Salem Partners LLC

Royalty Pharma

Natera, Inc.

Sun Pharmaceuticals and Taro Pharmaceuticals

Zydus Pharmaceutical, Inc.

Cadila Healthcare LTD.

PACT Pharma

Renibus Therapeutics, Inc.

Canopy Growth Corporation

Federation Bio

Avellino Lab USA, Inc.

OncoNano Medicine, Inc.

Columbia University

University of Pennsylvania

Wave Life Sciences Ltd

National Associate of Boards of Pharmacy

Sandoz Inc.

RWJBarnabas Health, Inc.

Envista Holdings Corporation

Lazarus3D, Inc.

Octagos Health, Inc.

Hikma Ventures

Yas Holding LLC

Work highlights

  • Advising Genentech on a wide variety of diligence and prosecution matters.
  • Advising Oxford Nanopore Technologies on a wide variety of strategic intellectual property counselling matters.
  • Advising Fujifilm and their various subsidiaries on all manner of IP issues over, including major patent litigation at the ITC and district court, licensing, patent counselling and prosecution.

Duane Morris LLP

The ‘diligent and knowledgeable‘ team at Duane Morris LLP assists clients with company formations through venture capital funds and public offerings, biotech and pharmaceutical licensing deals, and regulatory issues surrounding operations and marketing. Dana Ash and Shannon Sutherland are based in Philadelphia, with Ash handling product liability and toxic tort cases, and Sutherland advising on employment and commercial disputes. In the Boston office, Frederick Ball assists biologics and medical device manufacturers on state and federal FCA, anti-kickback, and advertising regulations, while Jonathan Lourie acts for medical device and research tool companies in transactions concerning drug delivery tech, therapeutics diagnostics, and antimicrobials. Based in Florida, Patrick Gallagher advises on dispute prevention and resolution, and regulatory issues concerning biosimilar medications and biologics, while Driscoll Ugarte represents emerging companies. Vicki Norton, who works out of the California office, focuses on life science patent counselling and litigation.


Practice head(s):

Dana Ash; Frederick Ball; Patrick Gallagher; Jonathan Lourie; Vicki Norton; Driscoll Ugarte; Shannon Sutherland

Other key lawyers:

Sean Zabaneh; Ryan Smith


‘The team’s foresight is crucial to ensuring patents that can sustain even the most serious litigations. Duane Morris has a good consistency in their service.’

‘They are diligent and knowledgeable with broad and comprehensive understanding of the technologies and updates in law and prosecution. Particularly Vicki Norton.’

Key clients

PeriphaGen, Inc.

Catalent Pharma Solutions

Optotune AG and Edmund Optics, Inc.

Wright Medical Technology, Inc.

The Jackson Laboratory

Ology Bioservices

Somerset Therapeutics


Mark Willis

Roundwood Capital, LLC

Scientific Air Management

Consolidated Water Co.

Scuti.AI L.L.C. (GStore LLC)

Allele Biotechnology

Work highlights

Jones Day

Jones Day’s ‘very strong‘ practice handles a variety of contentious and non-contentious matters for treatment centers and large pharmaceutical companies, including antitrust and consumer protection claims, product liability disputes, and patent interference proceedings. Kenneth Field co-heads the practice alongside Alexis Gilroy in Washington DC. Field has broad experience in antitrust and government investigations, while Gilroy maintains a digital health focused practice, routinely assisting clients with transactional and regulatory issues surrounding telehealth, telemedicine, and mobile health. Heather O’Shea bolsters the team from Chicago with her longstanding regulatory expertise in the biotech, pharmaceutical, and medical device industries, often advising clients on FCA, anti-kickback, and clinical research compliance.

Practice head(s):

Kenneth W. Field; Alexis S. Gilroy; Heather M. O’Shea

Other key lawyers:

Anthony Insogna; Maureen Bennet


‘Jones Day’s practice is very strong. They can always put together a strong team regardless of the issue the company is facing.’

‘Anthony Insogna has a long history in the life sciences industry and is very knowledgeable. He also has an incredible team around him.’

‘Maureen Bennet is very responsive and she really understands our business and the industry. She is practical. Jones Day have a broad global coverage and good legal network to cover most areas we work in.’

Key clients

Astellas Pharma

California Stem Cell Treatment Center, Inc.

Meridian Bioscience, Inc.

CCS Medical, Inc.

Organon & Co.

Sanofi-Aventis U.S. LLC

ToolGen, Inc.

Johnson & Johnson (“J&J”) and DePuy Synthes (“DePuy”)

Work highlights

Loeb & Loeb LLP

Loeb & Loeb LLP‘s chiefly New York based practice handles the full scope of life sciences mandates, including adverse event reporting and response, patent enforcement, and the approval of biosimilars and biologics products. Fran Stoller advises both public and private biotech, pharmaceutical, and technology companies on corporate and financing transactions, in addition to research and development collaborations. Mark Waddell handles the patent litigation side of the practice, representing drug companies in biosimilars and Hatch-Waxman related matters concerning exclusivity protection. Mitchell Nussbaum maintains a corporate and capital markets focused practice, routinely advising on private placements, IPOs, and proxy contests.


Practice head(s):

Fran Stoller; Mark Waddell; William Kramer; Michael Nussbaum

Key clients

Mountain Crest Acquisition Corp. II

Mountain Crest Acquisition Corp. III

Mountain Crest Acquisition Corp. V

Petra Acquisition Inc.

SPK Acquisition Corp.

Vickers Vantage Corp. I

Health Sciences Acquisitions Corporation 2 (HSAC2)

Genenta Science S.p.A.

DiaCarta, Inc.

Comera Life Sciences Holdings, Inc.

Titan Pharmaceuticals, Inc.

JATT Acquisition Corp.

ThinkEquity LLC

Boustead Securities, LLC

Lakeshore Acquisition I Corp.

Work highlights

  • Represented the issuer, Genenta Science S.p.A., in a foreign company U.S. IPO under SEC form F-1, and related regulatory and securities issues.
  • Represented Mountain Crest Acquisition Corp. V in its business combination with AUM Biosciences Pte. Ltd. The transaction reflected a pre-money equity value of $400 million for AUM.
  • Advised Titan Pharmaceuticals’ board of directors in connection with its various dealings with an activist shareholder.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

The large Boston-based team at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. assists clients with the full spectrum of transactional life sciences matters, product liability cases, and IP disputes. William Whelan has a great deal of experience advising biotech, medtech, and healthcare IT companies on venture capital financing and M&A, while Jonathan Kravetz acts for medical device companies on contractual and strategic capital markets and securities related issues. Lewis Geffen focuses on assisting pharmaceutical companies on corporate and licensing transactional matters. Thomas Wintner, an experienced IP and commercial litigator, routinely defends class actions and acts in patent and trade secret matters regarding molecular and cellular engineering and the Biologics Price Competition and Innovation Act.

Practice head(s):

William Whelan; Jonathan Kravetz; Lewis Geffen; Thomas Wintner

Other key lawyers:

John Cheney; Terri Shieh-Newton

Key clients


ProKidney LP

Intra-Cellular Therapies, Inc.

Wave Life Sciences

Fulgent Genetics

Myriad Genetics, Inc.

Pieris Pharmaceuticals, Inc.

G1 Therapeutics, Inc.

BeiGene Ltd.

Cardurion Pharmaceuticals

Work highlights

  • Advised ProKidney LP in its combination with Social Capital Suvretta Holdings Corp. III, a SPAC, and its subsequent listing on the Nasdaq. The deal will provide approximately $597 million in gross cash proceeds.
  • Represented BeiGene, Ltd. in its option, collaboration, and license agreement with pharmaceutical company Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan.
  • Advised Cardurion Pharmaceuticals, Inc. in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity.

Reed Smith LLP

The team of 'dedicated experts' at Reed Smith LLP assists clients with a myriad of issues, including bet the company investigations, FCA cases, and trade secret matters. Melissa Geist heads the practice alongside Scott Hasselman from Princeton and Washington DC respectively. California's Michael Sanders has longstanding expertise in representing medical device manufacturers and venture capital firms in series financings and pre-funded warrants. Austin based practitioner Rebecca Jones McKnight joined the team from DLA Piper LLP (US) in February 2022, contributing her expertise in FDA matters, with a particular emphasis on product distribution, creation, and development.

Practice head(s):

Melissa Geist; Scot Hasselman

Other key lawyers:

Michael Sanders; Deborah Gunny; Katy Basile


‘The firm has experts in every area and can collaborate seamlessly to ensure all needs are met.’

‘Dedicated experts that provide timely services.’ 

Work highlights

Robins Kaplan LLP

Robins Kaplan LLP houses a broad team of practitioners who handle issues pertaining to the Hatch-Waxman, and Biologics Price Competition and Innovation Acts. The team serves a varied client base of pharmaceutical and international bioscience companies, and medical systems operators. Christopher Laurus, who leads the group from Minneapolis, exhibits a great deal of expertise in patent infringements and exhaustions, while Cyrus Morton often appears before the PTAB and the USPTO in disputes.

Practice head(s):

Christopher Larus

Other key lawyers:

Cyrus Morton

Key clients

Collegium Pharmaceutical Inc.

The Trustees of the University of Pennsylvania

Medtronic, Inc.

Hikma Pharmaceuticals

Torrent Pharmaceuticals Ltd.

Topcon Medical Systems, Inc.

Gurnet Point Capital

BioDelivery Sciences International, Inc

Work highlights

  • Advising Collegium in a series of related patent cases against Purdue.
  • Represented Trustees of the University of Pennsylvania in a complex patent infringement matter against Eli Lilly and ImClone related to the manufacture and sale of Erbitux®.
  • The firm represented U.S. contact lens purchasers in an expansive antitrust class action against the four dominant manufacturers and the largest nationwide distributor of contact lenses, and reached settlements in excess of $118 million.

Skadden, Arps, Slate, Meagher & Flom LLP

The team at Skadden, Arps, Slate, Meagher & Flom LLP handles a broad range of transactional issues for life sciences companies, including acquisitions, federal shareholder suits, and mergers. The team serves a diverse range of clients, including pharmaceutical, biotech, and medical device companies. Key practitioners include Graham Robinson in Boston, Faiz Ahmad in Delaware, and Marie Gibson in New York.

Other key lawyers:

Graham Robinson; Faiz Ahmad; Marie Gibson

Work highlights

White & Case LLP

White & Case LLP houses a broad team which handles pharmaceutical antitrust damages cases, life science M&A and investments, and commercial litigation involving research agreements and contractual breaches. Peter Carney leads the team from Washington DC, drawing on his expertise in acting for domestic and overseas pharmaceutical companies in antitrust civil litigations and government investigations. New York-based antitrust litigator Robert Milne assists pharmaceutical clients with M&A transactions. Colleen Tracy James has since left the practice.

Practice head(s):

Peter Carney

Other key lawyers:

Robert Milne

Key clients






Boston Scientific

CM Life Sciences

Forest Laboratories


Johnson & Johnson (Jansen Pharmaceutical)

Hikma Pharmaceuticals




Samsung Bioepsis


Zimmer Biomet

Work highlights

  • Acted for Boston Scientific’s affiliate BTG International in litigation alleging monopolization in the sale of Zytiga.
  • Acted for AbbVie in the dismissal of all reverse-payment antitrust claims filed by nationwide class-action plaintiffs (direct and indirect purchasers) as well as nationwide retailers Walgreens and CVS.
  • Acted for Samsung Bioepis in a Seventh Circuit appeal of antitrust case relating to the blockbuster drug Humira.

Winston & Strawn LLP

Winston & Strawn LLP’s team handles the full range of life sciences mandates, including antitrust disputes, Hatch-Waxman litigations, and government investigations. Reed Stephens, who heads the practice from Washington DC, has a great deal of experience advising clients on FCA, anti-kickback, and Stark related cases, particularly in relation to fraud and abuse. Nimalka Wickramasekera divides her time between Los Angeles and Silicon Valley, handling all matters relating to patent and licensing disputes concerning medical devices and technology. David Dahlquist  has since left the practice to join the Department of Justice in August 2022, while Sharon Desh joined the Chicago practice in February 2022, contributing her experience in commercial litigation and antitrust matters.

Practice head(s):

Reed Stephens

Other key lawyers:

Nimalka Wickramasekera; George Lombardi; Sharon Desh

Key clients

Abbott Laboratories

Alphatec Holdings

Bayer (formerly Monsanto)

Galen Healthcare Solutions

Hikma Pharmaceuticals

MSN Laboratories

Otsuka America Pharmaceutical



Work highlights

  • Representing Hikma in national opiate litigation.
  • Representing Bayer (Monsanto) in Roundup® product liability trials.
  • Represented the Placement Agents in a SPAC business combination between ProKidney and Social Capital Suvretta Holdings Corp. III.